Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax
Key Highlights
- ➤Q2 revenue $7.2 million, up 28% year over year
- ➤Q2 net income before taxes reached $0.4 million, first-ever
- ➤Q2 EBITDA income $0.4 million, versus $0.2 million loss
- ➤U.S. revenue increased 93% on stronger distributor sales
- ➤Six-month revenue $13.6 million, up 41%; cash totaled $4.6 million
Expert Statements
Amy Trombly, CEO of Sonoma Pharmaceuticals
“We are very pleased to report another significant milestone for Sonoma: following our achievement of positive EBITDA last quarter, in the second fiscal quarter of 2027, Sonoma has delivered positive net income before income taxes for the first time in its history.”
Amy Trombly, CEO of Sonoma Pharmaceuticals
“Our results reflect the progress we are making in growing revenue while improving gross margins and maintaining disciplined control over operating expenses.”
Amy Trombly, CEO of Sonoma Pharmaceuticals
“U.S. revenue increased 93% this quarter, and total revenue grew 28%, demonstrating the growing contribution of our commercial efforts.”
Amy Trombly, CEO of Sonoma Pharmaceuticals
“We believe these results underscore the potential of our business model and our continued focus on building a stronger, more profitable company.”
BOULDER, CO / ACCESS Newswire / November 10, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn(®) technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2026.
"We are very pleased to report another significant milestone for Sonoma: following our achievement of positive EBITDA last quarter, in the second fiscal quarter of 2027, Sonoma has delivered positive net income before income taxes for the first time in its history," said Amy Trombly, CEO of Sonoma. "Our results reflect the progress we are making in growing revenue while improving gross margins and maintaining disciplined control over operating expenses. U.S. revenue increased 93% this quarter, and total revenue grew 28%, demonstrating the growing contribution of our commercial efforts. We believe these results underscore the potential of our business model and our continued focus on building a stronger, more profitable company."
Get started
Create a free account to read the full story.